Anti Hbs (Mikropartikül Immün Assay-Meia Veya Benzeri) Yüksekliği A new and fully automated microparticle enzyme immunoassay (IMX AUSAB,Abbott) is introduced for the detection of the existence of antibody to hepatitis B surface antifen (anti-HBS) anti hbs (mikropartikül immün assay-meia veya benzeri) yüksekliği.
The goal of the current study was to compare the IMx AUSAB with RIA (AUSAB, Abbott) and EIA (AUSAB EIA, Abbott) and ascertain whether utilising it with sera and plasma was feasible. The subjects were split into six groups based on the locations of the residents and the kind of immunisations administered. The following outcomes were attained: After testing 642 sera from 446 vaccine recipients as well as 196 additional residents of Okinawa and Miyazaki prefectures, 388 (87.0%), 392 (87.9%), and 359 (80.5%) tested positive for anti-HBs using IMx, RIA, and EIA. 96.6% of those who received recombinant vaccines tested positive for IMx, 96.2% for RIA, and 89.4% for EIA. Among subject vaccinated with plasma derived vaccines, 72.9% were found positive with IMx, 75.7% with RIA, and 68.5% EIA. Quantitative agreement between IMx and RIA among the six groups gave linear correlation coefficients ranging from 0.459 to 0.821.
Table of Contents
Intoduction Of Anti Hbs (Mikropartikül Immün Assay-Meia Veya Benzeri) Yüksekliği
We have a vaccination which is well established , safe and effective method of conferring long term protection against hepatitis B vrial infections,HCC known as hepatocellular carcinoma.
The decline rate of hepatitis B is due to vaccine (HBV)-related disease burden, prevalence of chronic HBV infections and HBV-related HCC among children and adolescents worldwide. Thailand adopted the policy of hepatitis B immunization in 1988, and universal hepatitis B vaccination of newborns has been integrated into the national expanded program of immunization since 1992. Available vaccines against hepatitis B have been shown to be safe and immunogenic.
Mothers having positive to hepatitis B surface antigen (HBsAg) and/or hepatitis B e-antigen (HBeAg) have a risk (70–90%) of chronically infecting their children.8-10 Three prospective studies were initiated in Thailand in 1986 to investigate the immunogenicity, reactogenicity and efficacy of a recombinant hepatitis B vaccine in children born to mothers that had different seropositivity status of HBsAg and HBeAg.
The results of these trials have been published for several time-points up to year 20 after the first hepatitis B dose. This paper reports the persistence of antibodies against hepatitis B surface antigen (anti-HBs) (NCT00240539) and anamnestic response to a hepatitis B vaccine challenge dose at the 20-y time-point (NCT00657657) in a cohort of subjects who had received a birth dose of hepatitis B immunoglobulin (HBIg) concomitantly with one dosage of hepatitis B vaccine, followed by three additional doses at 1, 2 and 12 mo with no booster dose in the primary study.
Methods. Anti Hbs (Mikropartikül Immün Assay-Meia Veya Benzeri) Yüksekliği (I) Measurement Of Hbsag By Lumipulse Hbsag-Hq Assay.
HSBsAg is basically measured basely on two step assay principle with a fully automatic chemiluminescent enzyme immunoassay system. The assay principle for this new reagent was based on that previously reported by Matsubara et al.. Briefly, samples were pretreated with a solution, including surfactant to disrupt HBV particles, to dissociate HBsAg from HBsAg–anti-HBs complexes and to denature epitopes to a linear form. Linearized HBsAg were then noticed using two monoclonal antibodies against external structural regions as determinant “a” and the internal epitope as a capture reagent, with two monoclonal antibodies coupled to alkaline phosphatase as the detector.
For the assay procedures, 100 μl blood serum and/or plasma examples together with 20 μl pretreatment answer were incubated with the monoclonal antibodies obligatory ferrite microparticles at 37°C for 10 min. After automatic washing, 250 μl of the alkaline phosphatase-labeled antibodies were added and further incubated at 37°C for 10 min. After the washing step, 200 μl substrate solution (AMPPD [3-(2′-spiroadamantane)-4-methoxy-4-(3″-phosphoryloxy)phenyl-1,2-dioxetane disodium salt]) (Applied Biosystems, Bedford, MA) was added and hatched at 37°C for 5 min.
The relative intensity of chemiluminescence was measured and the HBsAg attentiveness was calculated by comparison with a standard curve. The range of HBsAg concentrations assayed was 5 to 150,000 mIU/ml, and retesting was accepted with a 200-fold dilution of samples that exceeded this range. In the present study, the cutoff value of HBsAg concentration was set at 5 mIU/ml. HBsAg in blood serum was also quantified at the same intervals using the Abbott Architect HBsAg-QT assay (cutoff value, 50 mIU/ml).
(Ii) Quantification Of HBV DNA.
Serum HBV DNA was measured using the TaqMan PCR assay (Cobas TaqMan; Roche Molecular Systems [lower limit of detection, 2.1 log copies/ml]).
(Iii) Hbcrag Quantification.
CLEIA was used to test serum HBcrAg, as previously mentioned (12, 13). In brief, serum that had been prepared with sodium dodecyl sulphate was then incubated with monoclonal antibodies against denatured HBeAg and HBcAg. Following the washing step and incubation with secondary antibodies labelled with alkaline phosphatase, the relative chemiluminescence intensity was determined. The concentration of HBcAg was then determined by comparing the results to a standard curve that was created using a known concentration of recombinant HBeAg-containing peptide. Three log U/ml was the HBcrAg cutoff threshold. anti hbs (mikropartikül immün assay-meia veya benzeri) yüksekliği
(Iv) Anti-HB Quantification.
The anti-HBs in the Architect system were used to measure serum anti-HBs. When the concentration of anti-HBs was ≥10.0 mIU/ml, the material was deemed positive.